Orally available direct thrombin inhibitors (DTI) and direct activated factor X inhibitors (DFXaI) may replace vitamin K antagonists in patients needing long-term anticoagulant treatment. We investigated the influence on the fibrin network of anticoagulants with different modes of action: AR-H067637 (DTI), the active metabolite of AZD0837, apixaban (DFXaI), fondaparinux (indirect FXaI) and warfarin. Counteraction of the anticoagulant effect by FEIBA^® (Factor Eight Inhibitor Bypass Activity) was also investigated. Tissue factor, phospholipids and calcium were used to initiate coagulation in human platelet poor plasma. The permeability constant (Ks), reflecting the amount of buffer passing through the coagulum, was calculated and the fibrin network was visualized by 3D confocal microscopy. Warfarin (International Normalized Ratio 2-3) increased Ks in plasma by 28–50% compared with control. ‘Therapeutic’ plasma concentrations of AR-H067637 (0·3–0·6 μmol/l), apixaban (0·2–0·4 μmol/l) and fondaparinux (0·1–0·3 μmol/l) increased Ks by 72–91%, 58–76% and 36–53% respectively. Addition of FEIBA^® totally reversed the warfarin effect but only partially reversed effects of the other anticoagulants at concentrations that increased Ks by 50% or more. Fibrin network observed with 3D confocal microscopy agreed well with the permeability results. In conclusion, all examined anticoagulants rendered the fibrin network more porous. FEIBA^® reversed the increased permeability in warfarin plasma but had only partial effects on the other anticoagulants.

References

Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. (2008) Pharmacology and management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 160S–198S.
10.1378/chest.08-0670
CAS PubMed Web of Science® Google Scholar
Blombäck, B. & Bark, N. (2004) Fibrinopeptides and fibrin gel structure. Biophysical Chemistry, 112, 147–151.
10.1016/j.bpc.2004.07.013
CAS PubMed Web of Science® Google Scholar
Blombäck, B., Carlsson, K., Fatah, K., Hessel, B. & Procyk, R. (1994) Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thrombosis Research, 75, 521–538.
10.1016/0049-3848(94)90227-5
PubMed Web of Science® Google Scholar
Boos, C.J. & Lip, G.Y.H. (2006) Ximelagatran: an eulogy. Thrombosis Research, 118, 301–304.
10.1016/j.thromres.2006.02.012
CAS PubMed Web of Science® Google Scholar
Borris, L.C. (2009) Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint artroplasty. Expert Opinion on Pharmacotherapy, 10, 1083–1088.
10.1517/14656560902835513
CAS PubMed Web of Science® Google Scholar
Carreiro, J. & Ansell, J. (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opinion on Investigational Drugs, 17, 1937–1945.
10.1517/13543780802528625
CAS PubMed Web of Science® Google Scholar
Collet, J.P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G. & Weisel, J.W. (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1354–1361.
10.1161/01.ATV.20.5.1354
CAS PubMed Web of Science® Google Scholar
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. & Wallentin, L. (2009) RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139–1151.
10.1056/NEJMoa0905561
CAS PubMed Web of Science® Google Scholar
Deinum, J., Mattsson, C., Inghardt, T. & Elg, M. (2009) Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thrombosis and Haemostasis, 101, 1051–1059.
CAS PubMed Web of Science® Google Scholar
Elg, M., Carlsson, S. & Gustafsson, D. (2001a) Effect of Activated Prothrombin Complex Concentrate or recombinant Factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis Research, 101, 145–157.
10.1016/S0049-3848(00)00397-2
CAS PubMed Web of Science® Google Scholar
Elg, M., Carlsson, S. & Gustafsson, D. (2001b) Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anaesthetized rats and rabbits. Thrombosis Research, 101, 159–170.
10.1016/S0049-3848(00)00398-4
CAS PubMed Web of Science® Google Scholar
He, S., Cao, H., Antovic, A. & Blombäck, M. (2005a) Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagulation and Fibrinolysis, 16, 61–67.
10.1097/00001721-200501000-00010
CAS PubMed Web of Science® Google Scholar
He, S., Ekman, J.G. & Hedner, U. (2005b) The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thromasthenia. Journal of Thrombosis and Haemostasis, 3, 272–279.
10.1111/j.1538-7836.2005.01127.x
CAS PubMed Web of Science® Google Scholar
He, S., Ezban, M., Bark, N., Persson, E. & Hedner, U. (2009) Fibrin gel structure obtained with a FVIIa analogue with enhanced FXa-activating potential in haemophilia. Thrombosis and Haemostasis, 102, 790–792.
CAS PubMed Web of Science® Google Scholar
He, S., Blombäck, M., Bark, N., Johnsson, H. & Wallen, N.H. (2010) The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thrombosis and Haemostasis, 103, 1076–1084.
10.1160/TH09-05-0306
CAS PubMed Web of Science® Google Scholar
Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. & Weitz, J.I. (2008) Parenteral anticoagulants. Chest, 133, 141S–59S.
10.1378/chest.08-0689
CAS PubMed Web of Science® Google Scholar
Lip, G.Y.H., Rasmussen, L.H., Olsson, S.B., Jensen, E.C., Persson, A.L., Eriksson, U., Wåhlander, K.F. & on behalf of the Steering Committee. (2009) Oral direct inhibitor AZD 0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal, 30, 2832–2834.
10.1093/eurheartj/ehp318
CAS PubMed Web of Science® Google Scholar
Negrier, C., Dargaud, Y. & Bordet, J.C. (2006) Basic aspects of bypassing agents. Haemophilia, 12(Suppl 6), 48–53.
10.1111/j.1365-2516.2006.01366.x
CAS PubMed Web of Science® Google Scholar
Nishio, H., Ieko, M. & Nakabayashi, T. (2008) New therapeutic option for thromboembolism-dabigatran etexilate. Expert Opinion on Pharmacotherapy, 9, 2509–2517.
10.1517/14656566.9.14.2509
CAS PubMed Web of Science® Google Scholar
Pehrsson, S., Johansson, K., Kjaer, M. & Elg, M. (2010) Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Thrombosis and Haemostasis, 104, 1242–1249.
10.1160/TH09-10-0744
CAS PubMed Web of Science® Google Scholar
Raghavan, N., Frost, C.E., Yu, .Z., He, K., Zhang, H., Humphreys, W.G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P.C. & Zhang, D. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metabolism and Disposition, 37, 74–81.
10.1124/dmd.108.023143
CAS PubMed Web of Science® Google Scholar
Schulman, S. & Bijsterveld, N.R. (2007) Anticoagulants and their reversal. Transfusion Medicine Reviews, 21, 37–48.
10.1016/j.tmrv.2006.08.002
PubMed Web of Science® Google Scholar
Shantsila, E. & Lip, G.Y.H. (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Current Opinion in Investigational Drugs, 9, 1020–1033.
CAS PubMed Web of Science® Google Scholar
Váradi, K., Negrier, C., Berntorp, E., Astermark, J., Bordet, C., Morfini, M., Linari, S., Schwartz, H.P. & Turecek, P.L. (2003) Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostasis, 1, 2374–2380.
10.1046/j.1538-7836.2003.00450.x
CAS PubMed Web of Science® Google Scholar
Weitz, J.I., Hirsh, J. & Samama, M.M. (2008) New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 234S–256S.
10.1378/chest.08-0673
CAS PubMed Web of Science® Google Scholar
Wojcik, C., Schymik, M.L. & Cure, E.G. (2009) Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. International Journal of Emergency Medicine, 2, 217–225.
10.1007/s12245-009-0125-8
PubMed Google Scholar

Citing Literature

Volume152, Issue6

March 2011

Pages 758-765

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*

Summary

References

Citing Literature

References

Related

Information